Tyenne (tocilizumab-aazg) — United Healthcare

Initial criteria

• Diagnosis of moderately to severely active rheumatoid arthritis
• Patient has had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs) (e.g., methotrexate, leflunomide, sulfasalazine)
• Patient is not receiving Actemra or Tyenne in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

Reauthorization criteria

• Documentation of positive clinical response to Actemra or Tyenne therapy
• Patient is not receiving Actemra or Tyenne in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]

Approval duration

12 months